Long-term symptom improvement and patient satisfaction following catheter ablation of supraventricular tachycardia: insights from the German ablation registry
Standard
Long-term symptom improvement and patient satisfaction following catheter ablation of supraventricular tachycardia: insights from the German ablation registry. / Brachmann, Johannes; Lewalter, Thorsten; Kuck, Karl-Heinz; Andresen, Dietrich; Willems, Stephan; Spitzer, Stefan G; Straube, Florian; Schumacher, Burghard; Eckardt, Lars; Danilovic, Dejan; Thomas, Dierk; Hochadel, Matthias; Senges, Jochen.
in: EUR HEART J, Jahrgang 38, Nr. 17, 01.05.2017, S. 1317-1326.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Long-term symptom improvement and patient satisfaction following catheter ablation of supraventricular tachycardia: insights from the German ablation registry
AU - Brachmann, Johannes
AU - Lewalter, Thorsten
AU - Kuck, Karl-Heinz
AU - Andresen, Dietrich
AU - Willems, Stephan
AU - Spitzer, Stefan G
AU - Straube, Florian
AU - Schumacher, Burghard
AU - Eckardt, Lars
AU - Danilovic, Dejan
AU - Thomas, Dierk
AU - Hochadel, Matthias
AU - Senges, Jochen
N1 - Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2017. For permissions, please email: journals.permissions@oup.com.
PY - 2017/5/1
Y1 - 2017/5/1
N2 - Aims: To analyse outcomes of supraventricular tachycardia (SVT) ablations performed within a prospective German Ablation Quality Registry.Methods and results: Data from 12 566 patients who underwent catheter ablation of SVT between January 2007 and January 2010 to treat atrial fibrillation (AFIB, 37.2% of procedures), atrial flutter (AFL, 29.9%), atrioventricular nodal re-entrant tachycardia (AVNRT, 23.2%), atrioventricular re-entrant tachycardia (6.3%), and focal atrial tachycardia (AT, 3.4%) were prospectively collected. Patients were followed for at least 1 year. The periprocedural success rate was 96.3%, ranging from 84.3% (focal AT) to 98.9% (AVNRT). Kaplan-Meier mortality estimate at 1 year was 1.4% overall, and as high as 2.6% in the AFL group and 2.8% in the focal AT group. Recurrence of ablated or another symptomatic SVT was observed in 3783 (32.6%) of patients, ranging from 17.2% (AVNRT) to 45.6% (AFIB). Repeat ablation was performed in 12.0% of patients. After 1 year, 74.1% of survivors perceived ablation therapy as successful, 15.7% as partly successful, and 9.6% as unsuccessful. Even in those patients with arrhythmia recurrence, 76.0% perceived ablation as successful or partly successful and 89.6% would still undergo repeat ablation in the same institution.Conclusion: Ablation therapy for SVT is a safe procedure bringing symptomatic improvement and satisfaction to three quarters of patients after 1 year. Even in patients with arrhythmia recurrence, a high satisfaction level and adherence to the ablating institution could be documented. Strikingly high mortality and stroke rates in follow-up were observed in AFL patients, who apparently need consistent long-term anticoagulation and more medical attention.
AB - Aims: To analyse outcomes of supraventricular tachycardia (SVT) ablations performed within a prospective German Ablation Quality Registry.Methods and results: Data from 12 566 patients who underwent catheter ablation of SVT between January 2007 and January 2010 to treat atrial fibrillation (AFIB, 37.2% of procedures), atrial flutter (AFL, 29.9%), atrioventricular nodal re-entrant tachycardia (AVNRT, 23.2%), atrioventricular re-entrant tachycardia (6.3%), and focal atrial tachycardia (AT, 3.4%) were prospectively collected. Patients were followed for at least 1 year. The periprocedural success rate was 96.3%, ranging from 84.3% (focal AT) to 98.9% (AVNRT). Kaplan-Meier mortality estimate at 1 year was 1.4% overall, and as high as 2.6% in the AFL group and 2.8% in the focal AT group. Recurrence of ablated or another symptomatic SVT was observed in 3783 (32.6%) of patients, ranging from 17.2% (AVNRT) to 45.6% (AFIB). Repeat ablation was performed in 12.0% of patients. After 1 year, 74.1% of survivors perceived ablation therapy as successful, 15.7% as partly successful, and 9.6% as unsuccessful. Even in those patients with arrhythmia recurrence, 76.0% perceived ablation as successful or partly successful and 89.6% would still undergo repeat ablation in the same institution.Conclusion: Ablation therapy for SVT is a safe procedure bringing symptomatic improvement and satisfaction to three quarters of patients after 1 year. Even in patients with arrhythmia recurrence, a high satisfaction level and adherence to the ablating institution could be documented. Strikingly high mortality and stroke rates in follow-up were observed in AFL patients, who apparently need consistent long-term anticoagulation and more medical attention.
KW - Aged
KW - Atrial Fibrillation/mortality
KW - Atrial Flutter/mortality
KW - Catheter Ablation/mortality
KW - Female
KW - Follow-Up Studies
KW - Germany/epidemiology
KW - Hospital Mortality
KW - Humans
KW - Kaplan-Meier Estimate
KW - Male
KW - Middle Aged
KW - Patient Satisfaction
KW - Postoperative Complications/etiology
KW - Recurrence
KW - Registries
KW - Tachycardia, Atrioventricular Nodal Reentry/mortality
KW - Tachycardia, Supraventricular/mortality
KW - Treatment Outcome
U2 - 10.1093/eurheartj/ehx101
DO - 10.1093/eurheartj/ehx101
M3 - SCORING: Journal article
C2 - 28329395
VL - 38
SP - 1317
EP - 1326
JO - EUR HEART J
JF - EUR HEART J
SN - 0195-668X
IS - 17
ER -